Skip to main content
Springer Nature Link
Log in

Testosterone replacement therapy in male hypogonadism

  • Review Article
  • Published:
Save article
View saved research
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

In human males 6–7 mg of testosterone are secreted by the testes in a circadian rhythm with a nocturnal rise in testosterone followed by a decline during the day. Testosterone is necessary to induce and maintain secondary sexual characteristics, lean muscle mass, bone density and for normal sexual behaviour and cognitive function in men. Replacement therapy has been shown to be beneficial in men with overt hypogonadism. Natural testosterone should be used and not modified molecules. Testosterone is currently available in oral, intramuscular, subcutaneous and transdermal preparations. Recent advances in testosterone replacement therapy include testosterone gels which provide flexibility in dosing and minimal skin irritation resulting in good compliance, and the development of longer acting intramuscular preparations which result in more stable testosterone levels with longer injection intervals. All patients receiving testosterone should be carefully monitored for changes in hematocrit, liver function, lipid parameters and prostate specific antigen (PSA).This article reviews the current experience with the use of various forms of testosterone for the treatment of male hypogonadism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References

  1. Veldhuis J.D., King J.C, Urban R.J., et al. Operating characteristics of the male hypothalamopituitary-gonadal axis: Pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. J. Clin. Endocrinol. Metab. 1987, 65: 929–941.

    Article  PubMed  CAS  Google Scholar 

  2. Jenkins E.P., Hsieh C.L., Milatovich A., et al. Characterization and chromosomal mapping of a human steroid 5α-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991, 11: 1102–1112.

    Article  PubMed  CAS  Google Scholar 

  3. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., Russell D.W. Tissue distribution and ontogeny of steroid 5α-reductase isoenzyme expression. J. Clin. Invest. 1993, 92: 903–910.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Hsiao P.W., Lin D.L., Nakao R., Chang C. The linkage of Kennedy’s neuron disease to ARA 24, the first identified androgen receptor polyglutamine region-associated coactivator. J. Biol. Chem. 1999, 29: 20229–20234.

    Article  Google Scholar 

  5. Dejager S., Bry-Gauillard H., Bruckert E., et al. A comprehensive endocrine description of Kennedy’s disease revealing androgen insensitivity linked to CAG repeat length. J. Clin. Endocrinol. Metab. 2002, 87: 3893–3901.

    PubMed  CAS  Google Scholar 

  6. von Eckardstein S., Syska A., Gromoll J., Kamischke A., Simoni M., Nieschlag E. Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. J. Clin. Endocrinol. Metab. 2001, 86: 2585–2590.

    Google Scholar 

  7. Rajpert-De Meyts E., Leffers H., Petersen J.H., et al. CAG repeat length in androgen-receptor gene and reproductive variables in fertile and infertile men. Lancet 2002, 359: 44–46.

    Article  PubMed  CAS  Google Scholar 

  8. Zitzmann M., Brune M., Kornmann B., et al. The CAG repeat polymorphism in the AR gene affects high density ipoprotein cholesterol and arterial vasoreactivity. J. Clin. Endocrinol. Metab. 2001, 86: 4867–73.

    Article  PubMed  CAS  Google Scholar 

  9. Zitzmann M., Brune M., Kornmann B., Gromoll J., Junker R., Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin. Endocrinol. (Oxf.) 2001, 55: 649–57.

    Article  CAS  Google Scholar 

  10. Krithivas K., Yurgalevitch S.M., Mohr B.A., et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen evels in men. J. Endocrinol. 1999, 162: 137–142.

    Article  PubMed  CAS  Google Scholar 

  11. Hardy D.O., Scher H.I., Bogenreider T., et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J. Clin. Endocrinol. Metab. 1996, 81: 4400–4405.

    PubMed  CAS  Google Scholar 

  12. Harman S.M., Metler E.J., Tobin J.D., Pearson J., Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J. Clin. Endocrinol. Metab. 2001, 88: 724–731.

    Article  Google Scholar 

  13. Feldman H.A., Longcope C., Derby C.A., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 2002, 87: 589–98.

    Article  PubMed  CAS  Google Scholar 

  14. Nieschlag E., Lammers U., Freischem C.W., Langer K., Wickings E.J. Reproductive functions in young fathers and grandfathers. J. Clin. Endocrinol. Metab. 1982, 55: 676–681.

    Article  PubMed  CAS  Google Scholar 

  15. Mulligan T., Iranmanesh A., Veldhuis J.D. Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. J. Clin. Endocrinol. Metab. 2001, 86: 5547–553.

    Article  PubMed  CAS  Google Scholar 

  16. Gray A., Feldman H.A., McKinlay J.B., Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 1991, 73: 1016–1025.

    Article  PubMed  CAS  Google Scholar 

  17. Bremner W.J., Prinz P.N. A loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. 1983, 56: 278–1281.

    Article  Google Scholar 

  18. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 1999, 84: 2647–2653.

    PubMed  CAS  Google Scholar 

  19. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 1999, 84: 1966–1972.

    PubMed  CAS  Google Scholar 

  20. Morales A., Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 2002, 5: 74–86.

    Article  PubMed  CAS  Google Scholar 

  21. Davidson J.M., Camargo C.A., Smith E.R. Effects of androgen on sexual behaviour in hypogonadal men. J. Clin. Endocrinol. Metab. 1979, 48: 955–958.

    Article  PubMed  CAS  Google Scholar 

  22. Finkelstein J.S. Androgens and bone metabolism. In: Nieschlag E., Behre H.M. (Eds.), Testosterone: Action, Deficiency, Substitution, 2nd ed. Springer-Verlag, Berlin, Heidelberg, 1998, p.187.

    Chapter  Google Scholar 

  23. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 1997, 82: 2386–2390.

    Article  PubMed  CAS  Google Scholar 

  24. Bhasin S., Bross R., Storer T.W., Casaburi R. Androgens and muscles. In: Nieschlag E. and Behre H.M. (Eds.), Testosterone: Action, Deficiency, Substitution, 2nd ed. Springer-Verlag, Berlin, Heidelberg, 1998, p. 209.

    Chapter  Google Scholar 

  25. Rolf C., von Eckardstein S., Koken U., Nieschlag E. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and eptin seen in healthy ageing men: results of a cross-sectional study. Eur. J. Endocrinol. 2002, 146: 505–11.

    Article  PubMed  CAS  Google Scholar 

  26. Behre H.M., Nieschlag E. Comparative pharmacokinetics of testosterone esters. In: Nieschlag E. and Behre H.M. (Eds.), Testosterone: Action, Deficiency, Substitution, 2nd ed. Springer-Verlag, Berlin, Heidelberg, 1998, p. 329.

    Chapter  Google Scholar 

  27. Bals-Pratsch M., Knuth U.A., Yoon Y.D., Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986, 2: 943–946.

    Article  PubMed  CAS  Google Scholar 

  28. Cunningham G.R., Cordero E., Thornby J.I. Testosterone replacement with transdermal therapeutic systems. J.A.M.A. 1989, 261: 2525–2530.

    Article  PubMed  CAS  Google Scholar 

  29. Behre H.M., von Eckardstein S., Kliesch S., Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin. Endocrinol. (Oxf.) 1999, 50: 629–635.

    Article  CAS  Google Scholar 

  30. Meikle W.A., Arver S., Dobs A.S., Sanders S.W., Rajaram L., Mazer N.A. Pharmacokinetics and metabolism of a permeation enhanced testosterone transdermal system in hypogonadal men: influence of application site — a clinical research study. J. Clin. Endocrinol. Metab. 1996, 81: 1832–1840.

    PubMed  CAS  Google Scholar 

  31. Arver S., Dobs A.S., Meikle A.W., et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin. Endocrinol. (Oxf.) 1997, 47: 727–737.

    Article  CAS  Google Scholar 

  32. Arver S.A., Dobs A.S., Meikle A.W., Allen R.P., Sanders S.W., Mazer N.A. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J. Urol. 1996, 155: 1604–1608.

    Article  PubMed  CAS  Google Scholar 

  33. Meikle A.W., Arver S., Dobs A.S., et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997, 49: 191–196.

    Article  PubMed  CAS  Google Scholar 

  34. Swerdloff R.S., Wang C., Cunningham G., et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. 2000, 85: 4500–4515.

    PubMed  CAS  Google Scholar 

  35. Wang C., Swerdloff R.S., Iranmanesh A., et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 2000, 85: 2839–2853.

    PubMed  CAS  Google Scholar 

  36. Wang C., Swerdloff R.S., Iranmanesh A., et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. (Oxf.) 2001, 54: 739–750.

    Article  Google Scholar 

  37. Rolf C., Knie U., Lemmnitz G., Nieschlag E. Interpersona testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin. Endocrinol. (Oxf.) 2002, 56: 637–641.

    Article  CAS  Google Scholar 

  38. Rolf C., Kemper S., Lemmnitz G., Eickenberg U., Nieschlag E. Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. Eur. J. Endocrinol. 2002, 146: 673–679.

    Article  PubMed  CAS  Google Scholar 

  39. Schaison G., Couzinet B. Percutaneous dihydrotestosterone treatment. In: Nieschlag E. and Behre H.M. (Eds.), Testosterone: Action, Deficiency, Substitution, 2nd ed. Springer-Verlag, Berlin, Heidelberg, 1998, p. 423.

    Chapter  Google Scholar 

  40. Wang C., Swerdloff R.S. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J. Clin. Endocrinol. Metab. 2002, 87: 1462–1466.

    Article  PubMed  CAS  Google Scholar 

  41. Delanoe D., Fougeyrollas B., Meyer L., Thonneau P. Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1984, 1: 276.

    Article  PubMed  CAS  Google Scholar 

  42. Ly LP., Jimenez M., Zhuang T.N., Celermajer D.S., Conway A.J., Handelsman D.J. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J. Clin. Endocrinol. Metab. 2001, 86: 4078–4088.

    Article  PubMed  CAS  Google Scholar 

  43. Handelsman D.J. Clinical pharmacology of testosterone pellet implants. In: Nieschlag E. and Behre H.M. (Eds.), Testosterone: Action, Deficiency, Substitution, ed. 2. Springer-Verlag, Berlin, Heidelberg, 1998, p. 349.

    Chapter  Google Scholar 

  44. Behre H.M., Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocrinol. Metab. 1992, 75: 1204–1210.

    PubMed  CAS  Google Scholar 

  45. von Eckardstein S., Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J. Androl. 2002, 23: 419–425.

    Google Scholar 

  46. Kamischke A., Heuermann T., Krüger K., et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J. Clin. Endocrinol. Metab. 2002, 87: 530–539.

    Article  PubMed  CAS  Google Scholar 

  47. Cummings D.E., Kumar N., Bardin D.W., Sundaram K., Bremmner W.J. Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J. Clin. Endocrinol. Metab. 1998, 83: 4212–4219.

    PubMed  CAS  Google Scholar 

  48. Anderson R.A., Martin C.W., Kung A.W., et al. 7α-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J. Clin. Endocrinol. Metab. 1999, 84: 3556–3562.

    PubMed  CAS  Google Scholar 

  49. Salehian B., Wang C., Alexander G., et al. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate — a clinical research center study. J. Clin. Endocrinol. Metab. 1995, 80: 3567–3575.

    PubMed  CAS  Google Scholar 

  50. Wang C., Eyre D.R., Clark R., et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men — a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81: 3654–3662.

    PubMed  CAS  Google Scholar 

  51. Dobs A.S., Hoover D.R., Chen M.C., Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J. Clin. Endocrinol. Metab. 1998, 83: 33–39.

    PubMed  CAS  Google Scholar 

  52. Morales A., Johnston B., Heaton J.P., Lundie M. Testosterone supplementation for hypogonadal impotence assessment of biochemical measures and therapeutic outcomes. J. Urol. 1997, 157: 849–854.

    Article  PubMed  CAS  Google Scholar 

  53. Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. Metab. 1997, 82: 3793–3796.

    Article  PubMed  CAS  Google Scholar 

  54. Sandblom R.E., Matsumoto A.M., Schoene R.B., Lee K.A., Giblin E.C., Bremner W.J., Pierson D.J. Obstructive sleep apnea induced by testosterone administration. N. Engl. J. Med. 1983, 308: 508–510.

    Article  PubMed  CAS  Google Scholar 

  55. Luboshitzky R., Aviv A., Hefetz A., et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J. Clin. Endocrinol. Metab. 2002, 87: 3394–3398.

    Article  PubMed  CAS  Google Scholar 

  56. Behre H.M., Bohmeyer J., Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin. Endocrinol. (Oxf.) 1994, 40: 341–349.

    Article  CAS  Google Scholar 

  57. Negro-Vilar A. Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 1999, 84: 3459–3462.

    Article  PubMed  CAS  Google Scholar 

  58. Nieschlag E., Behre H.M. (Eds.), Andrology: Male reproductive health and dysfunction, 1st ed. Springer-Verlag, Heidelberg, New York, 1997, p. 81.

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Reproductive Medicine, University of Münster, Domagkstrasse 11, D-48129, Münster, Germany

    M. M. Byrne &  E. Nieschlag

Authors
  1. M. M. Byrne
    View author publications

    Search author on:PubMed Google Scholar

  2. E. Nieschlag
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to E. Nieschlag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Byrne, M.M., Nieschlag, E. Testosterone replacement therapy in male hypogonadism. J Endocrinol Invest 26, 481–489 (2003). https://doi.org/10.1007/BF03345206

Download citation

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1007/BF03345206

Key-words